These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2381619)
1. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer. Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619 [TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936 [TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer. Yeh LS; Hung YC; Kao A; Lin CC; Lee CC Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974 [TBL] [Abstract][Full Text] [Related]
4. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
5. Role of Ca 125 as tumor marker in ovarian carcinoma. Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052 [TBL] [Abstract][Full Text] [Related]
6. [Tumor marker combination versus second-look operation in ovarian cancer]. Lahousen M; Stettner H; Pürstner P; Pickel H Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187 [TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K]. Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444 [TBL] [Abstract][Full Text] [Related]
8. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
9. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer. Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201 [TBL] [Abstract][Full Text] [Related]
10. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403 [TBL] [Abstract][Full Text] [Related]
11. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer]. Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692 [TBL] [Abstract][Full Text] [Related]
13. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring. Koebl H; Tatra G; Bieglmayer C Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680 [TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in gynecologic diseases]. Geyer H; Kleine W Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991 [TBL] [Abstract][Full Text] [Related]
15. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164 [TBL] [Abstract][Full Text] [Related]
16. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?]. Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273 [No Abstract] [Full Text] [Related]
17. [The value of CA 125 determination in the serum of patients with ovarian cancer]. Bartel U; Johannsen B; Elling D Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673 [TBL] [Abstract][Full Text] [Related]
18. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases]. Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340 [TBL] [Abstract][Full Text] [Related]
19. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Jacobs IJ; Oram DH; Bast RC Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694 [TBL] [Abstract][Full Text] [Related]
20. Serum tumor markers in colorectal cancer staging, grading, and follow-up. Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]